Octanol to Treat Essential Tremor
NCT00080366 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 14
Last updated 2007-04-04
Summary
This study will evaluate the effectiveness of 1-octanol, a substance similar to alcohol but less intoxicating, for treating essential tremor. Essential tremor is an involuntary shaking, usually of the hands, for which there is no satisfactory treatment. It affects about 1.4 percent of the general U.S. population, with the figure climbing to nearly 4 percent among people over 40. Results of two previous NIH studies have shown 1-octanol to be promising as a potential new treatment. This study will test the effectiveness of 1-octanol on essential tremor at doses lower than those given previously.
Patients 21 years old and older with essential tremor may be eligible for this study. Participants are admitted to the NIH Clinical Center for two treatment periods of 1 week each, with a 1-week break at home between treatments. Before beginning treatment, participants undergo a medical history, physical examination, blood and urine tests, and an electrocardiogram (EKG). In addition, tremors are measured using accelerometry, a procedure in which a small device, mounted on a piece of cardboard, is taped to the patient's hand for about 30 minutes.
Patients are randomly assigned to one of two groups. One group takes 2 to 4 capsules of 1-octanol 3 times a day for 1 week, followed by a 1-week "washout" period (no treatment), and then 2 to 4 capsules of placebo 3 times a day for 1 week. Following the same dosage schedule, the second group takes placebo the first week, followed by the washout period and then 1-octanol treatment. Blood pressure and pulse are measured at 15, 30, and 60 minutes after the first dose of the day and then 3 times a day each day of hospitalization, EKG and blood draws are done every other day during hospitalization, and blood is drawn again 1 week after the end of the study. Patients evaluate their tremor daily according to a tremor scale and are also rated according to an alcohol intoxication scale.
Conditions
Interventions
- DRUG
-
1-Octanol
Sponsors & Collaborators
-
National Institute of Neurological Disorders and Stroke (NINDS)
lead NIH
Study Design
- Purpose
- TREATMENT
Eligibility
- Min Age
- 21 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-03-31
- Completion
- 2007-03-31
Countries
- United States
Study Locations
More Related Trials
-
Baclofen for Treating Anxiety and Alcoholism
NCT01751386 ·Status: COMPLETED ·Phase: PHASE2
-
Oxytocin Treatment of Alcohol Dependence
NCT02251912 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Exploratory Plasmatic Markers of Alcohol Withdrawal
NCT05216705 ·Status: COMPLETED
-
Baclofen for the Treatment of Alcohol Drinkers
NCT01604330 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Research on Translational Outcomes of Alcohol (Project RETRO)
NCT04742348 ·Status: WITHDRAWN ·Phase: PHASE4
-
Oxytocin Treatment of Alcohol Withdrawal
NCT01212185 ·Status: COMPLETED ·Phase: PHASE1
-
Deep Brain Stimulation for Refractory Alcoholism
NCT01798888 ·Status: WITHDRAWN ·Phase: PHASE1
-
EtOH Interaction Study
NCT00887367 ·Status: COMPLETED ·Phase: PHASE1
-
Preventing Alcohol Withdrawal With Oral Baclofen
NCT01937364 ·Status: TERMINATED ·Phase: PHASE2
-
Effect of Endotoxin on Alcohol Consumption
NCT04527185 ·Status: COMPLETED ·Phase: PHASE2
-
Using Transcutaneous Auricular Vagus Nerve Stimulation to Treat Acute Alcohol Withdrawal
NCT04159909 ·Status: WITHDRAWN ·Phase: NA
-
Acamprosate to Reduce Symptoms of Alcohol Withdrawal
NCT00106106 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacotherapy and Mechanisms of Sleep Disturbance in Alcohol Dependence
NCT01014533 ·Status: COMPLETED ·Phase: NA
-
Cannabinoids and Cerebellar-Motor Functioning
NCT01853020 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Remote Treatment of Alcohol Withdrawal
NCT04858490 ·Status: COMPLETED ·Phase: NA
-
Psilocybin-assisted Therapy for Alcohol Use Disorder
NCT06444243 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Ketamine for the Treatment for Alcohol Use Disorder in the ED
NCT05661669 ·Status: WITHDRAWN ·Phase: PHASE2
-
Efficacy and Safety of High Dose Baclofen for Alcohol Dependence
NCT01980706 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Ketone Supplementation on Alcohol Withdrawal and Brain Metabolism in Alcohol Use Disorder
NCT06559995 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Pregabalin as Treatment for Alcohol Use Disorder
NCT03256253 ·Status: COMPLETED ·Phase: PHASE2
-
Preliminary Human Trial of NPI-028
NCT00010907 ·Status: WITHDRAWN ·Phase: PHASE2
-
Effect of LY686017 on Alcohol Craving
NCT00310427 ·Status: COMPLETED ·Phase: PHASE2
-
Ketamine/Placebo Family History Positive Study
NCT00588952 ·Status: COMPLETED ·Phase: NA
-
The Effect of Naltrexone on Alcohol Craving and on Brain Activity During Alcohol Infusion
NCT00667771 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Computer-Assisted Self-Administration of Ethanol
NCT00713492 ·Status: COMPLETED ·Phase: PHASE1